Literature DB >> 17625603

Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.

T S Larsen, N Pallisgaard, M B Møller, H C Hasselbalch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17625603     DOI： 10.1038/sj.leu.2404861

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.

Authors:  Koichi Takahashi; Keyur P Patel; Hagop Kantarjian; Rajyalakshmi Luthra; Sherry Pierce; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2013-09-25       Impact factor: 22.113

2.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

3.  Gain of function in Jak2V617F-positive T-cells.

Authors:  G Nishanth; D Wolleschak; C Fahldieck; T Fischer; A Mullally; F Perner; T M Schnöder; S Just; F H Heidel; D Schlüter
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

4.  Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Authors:  Anders Lindholm Sørensen; Stine Ulrik Mikkelsen; Trine Alma Knudsen; Mads Emil Bjørn; Christen Lykkegaard Andersen; Ole Weis Bjerrum; Nana Brochmann; Dustin Andersen Patel; Lise Mette Rahbek Gjerdrum; Daniel El Fassi; Torben A Kruse; Thomas Stauffer Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Christina Ellervik; Niels Pallisgaard; Mads Thomassen; Lasse Kjær; Vibe Skov; Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-12-26       Impact factor: 9.941

5.  Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.

Authors:  Shuichi Shirane; Marito Araki; Soji Morishita; Yoko Edahiro; Yoshitaka Sunami; Yumi Hironaka; Masaaki Noguchi; Michiaki Koike; Eriko Sato; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-12-19       Impact factor: 2.490

6.  A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.

Authors:  Lasse Kjær; Maj Westman; Caroline Hasselbalch Riley; Estrid Høgdall; Ole Weis Bjerrum; Hans Hasselbalch
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

7.  Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.

Authors:  Martin M J Kirschner; Mirle Schemionek; Claudia Schubert; Nicolas Chatain; Stephanie Sontag; Susanne Isfort; Nadina Ortiz-Brüchle; Karla Schmitt; Luisa Krüger; Klaus Zerres; Martin Zenke; Tim H Brümmendorf; Steffen Koschmieder
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

8.  The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Authors:  Margherita Perricone; Nicola Polverelli; Giovanni Martinelli; Lucia Catani; Emanuela Ottaviani; Elisa Zuffa; Eugenia Franchini; Arbana Dizdari; Dorian Forte; Elena Sabattini; Michele Cavo; Nicola Vianelli; Francesca Palandri
Journal:  Oncotarget       Date:  2017-06-06

Review 9.  Low-Risk Essential Thrombocythemia: A Comprehensive Review.

Authors:  Andrew J Robinson; Anna L Godfrey
Journal:  Hemasphere       Date:  2021-01-27

10.  The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.

Authors:  Amina Kurtovic-Kozaric; Erna Islamagic; Hana Komic; Nurija Bilalovic; Izet Eminovic; Adnan Burekovic; Amna Uzunovic; Sabira Kurtovic
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.